ImmunityBio Inc. Common Stock vs Ventas Inc. Common Stock — how do they compare? ImmunityBio Inc. Common Stock trades at $10 (market cap $10.33B), while Ventas Inc. Common Stock trades at $82.53 (market cap $41.06B). The key difference: Ventas Inc. Common Stock is far larger — about 4× ImmunityBio Inc. Common Stock's market cap, and Ventas Inc. Common Stock pays a 2.6% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and Ventas Inc. Common Stock for 0 Days on average.
| IBRX | VTR | |
|---|---|---|
Market Cap | $10.33B | $41.06B |
Volume | 11,745,198 | 4,174,820 |
Sector | Health | Real Estate |
52-Week High | $11.55 | $100.53 |
52-Week Low | $1.98 | $67.45 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.79B | $53.78B |
Dividend Yield | — | 2.6% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →Ventas is a real estate investment trust focused on healthcare properties. Its portfolio includes senior housing, medical office buildings, and research-related facilities.
Read more on VTR →